Venaxis Inc: (NASD: APPY)
$1.69
0.04 (2.42%)
Volume 26,028
May 21 02:36 PM ET
Zacks Rank: NA 
| |
Overview Quote
Stock Activity
| Day Low - High | 1.65 - 1.69 |
| 52wk Low - High | 1.18 - 3.96 |
| Previous Close | 1.65 |
| Avg. Volume | 71,497 |
| Industry | MED PRODUCTS |
| Market Cap | 15.94 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.87 |
| PE (Forward) | 0.00 |
| Current Year Est. | 0.00 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
|
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
179 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | NA |
| Current Quarter Estimate | NA |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 05-20-2013 |
| EPS Last Year | -3.58 |
| Expected Earnings Growth | NA |
Company Description
Venaxis, Inc. is a biomedical diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test, APPY1. APPY1 is being developed initially for pediatric, adolescent and young adult patients with abdominal pain. Venaxis, Inc., formerly known as AspenBio Pharma, Inc., is based in Castle Rock, Colorado.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| CONCEPTUS INC | CPTS | 30.92 | |
|
| ATRICURE INC | ATRC | 9.05 | |
|
| INVIVO THERAPT | NVIV | 2.89 | |
|
| TRANS1 INC | TSON | 1.69 | |
|
| ABAXIS INC | ABAX | 44.67 | |
|
| ADVAXIS INC | ADXS | 0.05 | |
|
| BAXTER INTL | BAX | 72.94 | |
|
| BIO-RAD LABS -A | BIO | 116.41 | |
|
| BIOLIFE SOL INC | BLFS | 0.41 | |
|
| BOSTON SCIENTIF | BSX | 9.25 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Zacks #1 Rank Additions for Tuesday
Jun 19, 2012
Zacks #1 Rank Additions for Tuesday
Jun 05, 2012
Report Not Available
Financials
| EPS TTM | -3.58 |
| Sales | 0 |
| Net Income | -10 |
| Price/Earnings | NA |
| Price/Book | 1.90 |
| Price/Cash Flow | 0.04 |
| Price/Sales | 354.27 |
News
Venaxis Inc names Dr Stephen A Williams to board - M2
Apr 19, 2013
Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors - Benzinga
Apr 18, 2013
Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of Directors - Pr Newswire
Apr 18, 2013
Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test - Pr Newswire
Mar 26, 2013
Venaxis Inc wins additional commercial development agreements for APPY1 in Italy and Turkey - M2
Mar 19, 2013
Venaxis to Provide Fourth Quarter 2012 Business Update - Pr Newswire
Mar 19, 2013
Venaxis Secures Additional European Commercial Development Agreements for APPY1 - Pr Newswire
Mar 18, 2013
Venaxis to Present at 25th Annual ROTH Conference - Pr Newswire
Mar 11, 2013
Broker Recommendations
| Current ABR | 3.00 |
| ABR (Last Week) | 3.00 |
| # of recs in ABR | 1 |
| Average Target Price | 2.50 |
| Industry Rank by ABR | 179 out of 265 |
| Rank in Industry | NA |
